- Home
- YOSH vs CHEK Comparison
YOSH vs CHEK Comparison
Compare YOSH & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YOSH
- CHEK
- Stock Information
- Founded
- YOSH 2016
- CHEK 2004
- Country
- YOSH United States
- CHEK Israel
- Employees
- YOSH N/A
- CHEK N/A
- Industry
- YOSH Restaurants
- CHEK Medical Electronics
- Sector
- YOSH Consumer Discretionary
- CHEK Health Care
- Exchange
- YOSH Nasdaq
- CHEK Nasdaq
- Market Cap
- YOSH 5.6M
- CHEK 5.1M
- IPO Year
- YOSH 2022
- CHEK 2015
- Fundamental
- Price
- YOSH $3.65
- CHEK $0.61
- Analyst Decision
- YOSH
- CHEK
- Analyst Count
- YOSH 0
- CHEK 0
- Target Price
- YOSH N/A
- CHEK N/A
- AVG Volume (30 Days)
- YOSH 31.1K
- CHEK 14.0K
- Earning Date
- YOSH 11-19-2024
- CHEK 02-14-2025
- Dividend Yield
- YOSH N/A
- CHEK N/A
- EPS Growth
- YOSH N/A
- CHEK N/A
- EPS
- YOSH N/A
- CHEK N/A
- Revenue
- YOSH $11,652,880.00
- CHEK N/A
- Revenue This Year
- YOSH N/A
- CHEK N/A
- Revenue Next Year
- YOSH N/A
- CHEK N/A
- P/E Ratio
- YOSH N/A
- CHEK N/A
- Revenue Growth
- YOSH 25.97
- CHEK N/A
- 52 Week Low
- YOSH $2.73
- CHEK $0.61
- 52 Week High
- YOSH $8.60
- CHEK $3.45
- Technical
- Relative Strength Index (RSI)
- YOSH 46.13
- CHEK 19.90
- Support Level
- YOSH $3.64
- CHEK $0.61
- Resistance Level
- YOSH $3.96
- CHEK $0.63
- Average True Range (ATR)
- YOSH 0.30
- CHEK 0.04
- MACD
- YOSH 0.07
- CHEK -0.00
- Stochastic Oscillator
- YOSH 53.91
- CHEK 0.00
About YOSH Yoshiharu Global Co.
Yoshiharu Global Co is a restaurant operator. The company has one reportable segment, consisting of operating its stores. Yoshiharu serves the perfect, ideal ramen, as well as offers customers a wide variety of sushi, bento menus, and other favorite Japanese cuisines. It owns and operates restaurant stores.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.